Skip to main content
Clinical Trials/NCT01915953
NCT01915953
Unknown
Not Applicable

A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP

OrSense, Ltd.1 site in 1 country500 target enrollmentFebruary 2011
ConditionsAnemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Anemia
Sponsor
OrSense, Ltd.
Enrollment
500
Locations
1
Primary Endpoint
compre the Hb values from the NBM200 series gainst the Hb from the lab blood analyser on Hematology pateints
Last Updated
12 years ago

Overview

Brief Summary

The purpose of the study is to define the precision, accuracy and variability of the NBM-200 system in non invasive blood Hemoglobin (Hb) measurements relative to the laboratory blood analyzer by comparing two consecutive Hb values obtained by the NBM system to venous values.

Detailed Description

Each subject will be placed in a comfortable position in a temperature regulated room. Participants will have two consecutive non invasive (NBM) measurements taken which involves inserting the thumb into a ring shaped sensor. After each non invasive measurement the sensor will be removed. Each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the Hb values. The two non invasive measurements will be performed using the same finger. After the NBM system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated complete blood count or Hb blood analyzers.

Registry
clinicaltrials.gov
Start Date
February 2011
End Date
December 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants aged 18 years and over

Exclusion Criteria

  • Participants under the age of 18 years
  • Patients with significant deformity, degenerative changes or oedema of the fingers or hand
  • Patients with localized infection, ulceration or skin breaks involving the fingers
  • Patients with vascular disease or Raynaud's phenomenon affecting the fingers (vasospasm)
  • Participants who are unable to give informed written consent

Outcomes

Primary Outcomes

compre the Hb values from the NBM200 series gainst the Hb from the lab blood analyser on Hematology pateints

Time Frame: 1 day

Study Sites (1)

Loading locations...

Similar Trials